Floatz logo

gi-101a

Metastatic Solid Tumor

GI Innovation, Inc.Phase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

131 Active assets in the Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Epirubicin
InSilico Medicine Hong Kong Limited
Phase 2CCC
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2CCC
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2CCC
Nivolumab
Lantern Pharma Inc.
Phase 2CCC
Trastuzumab Emtansine
M.D. Anderson Cancer Center
Phase 2CCC

View all 50 →

Same molecule, other indications

gi-101a is also rated in:

nonpapillary renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell squamous lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →